<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34742052</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-0334</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Season>Nov-Dec</Season>
            </PubDate>
          </JournalIssue>
          <Title>Diabetes &amp; metabolic syndrome</Title>
          <ISOAbbreviation>Diabetes Metab Syndr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molnupiravir in COVID-19: A systematic review of literature.</ArticleTitle>
        <Pagination>
          <StartPage>102329</StartPage>
          <MedlinePgn>102329</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dsx.2021.102329</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1871-4021(21)00349-0</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Molnupiravir is a newer oral antiviral drug that has recently been tested in COVID-19. We aim to conduct a systematic review of literature to find out the efficacy and safety of molnupiravir in patients with COVID-19.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched the electronic database of PubMed, MedRxiv and Google Scholar from inception until October 15, 2021, using MeSH keywords. Ongoing trials of molnupiravir in COVID-19 were additionally searched from the ClinicalTrials.Gov and ctri.nic.in/Clinicaltrials. We retrieved all the available granular details of phase 1 to 3 studies of molnupiravir in COVID-19. Subsequently we reviewed the results narratively.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Two phase 1 double-blind, randomized, placebo-controlled (DBRPC) studies of molnupiravir showed that 1600 mg daily dose is safe and tolerable, without any serious adverse events up to 5.5 days. One phase 2 DBPRC study found significantly lower time to clearance (RNA negativity) with molnupiravir 800 mg twice daily compared to the placebo (log-rank p value = 0.013) in mild to moderate COVID-19. Interim report of one phase 3 DBRPC study in non-hospitalized COVID-19 found a significant reduction in the risk of hospital admission or death by 50% (p = 0.0012). However, no significant benefit was observed with molnupiravir in the later stage of moderate to severe COVID-19.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Molnupiravir is first oral antiviral drug to demonstrate a significant benefit in reducing hospitalization or death in mild COVID-19 and could be an important weapon in the battle against SARS-CoV-2. However, its role in moderate to severe COVID-19 is questionable and more studies are needed.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Awadhesh Kumar</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>G. D Hospital &amp; Diabetes Institute, Kolkata, West Bengal, India. Electronic address: drawadheshkumarsingh@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Akriti</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Jawaharlal Nehru Medical College &amp; Hospital, Kalyani, West Bengal, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Ritu</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>G. D Hospital &amp; Diabetes Institute, Kolkata, West Bengal, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Misra</LastName>
            <ForeName>Anoop</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Fortis C-DOC Hospital for Diabetes &amp; Allied Sciences, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Diabetes Metab Syndr</MedlineTA>
        <NlmUniqueID>101462250</NlmUniqueID>
        <ISSNLinking>1871-4021</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
          <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">EIDD-2801</Keyword>
        <Keyword MajorTopicYN="N">MK-4482</Keyword>
        <Keyword MajorTopicYN="N">Molnupiravir</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest Nothing to declare for all authors.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>20</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34742052</ArticleId>
        <ArticleId IdType="pmc">PMC8556684</ArticleId>
        <ArticleId IdType="doi">10.1016/j.dsx.2021.102329</ArticleId>
        <ArticleId IdType="pii">S1871-4021(21)00349-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cannalire R, Cerchia C, Beccari AR, et al. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities. J Med Chem. DOI: 10.1021/acs.jmedchem.0c01140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7688049</ArticleId>
            <ArticleId IdType="pubmed">33186044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subissi L., Posthuma C.C., Collet A. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3900–E3909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4169972</ArticleId>
            <ArticleId IdType="pubmed">25197083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA. 2001;98:6895–6900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC34449</ArticleId>
            <ArticleId IdType="pubmed">11371613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini M.L., et al.  Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93:24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.-J., Hart M., Natchus M.G., Painter G.R., Plemper R.K. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res. 2020;218:16–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7568909</ArticleId>
            <ArticleId IdType="pubmed">31945316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan T.P., Sims A.C., Zhou S., et al.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 29;12(541)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabinger F., Stiller C., Schmitzová J., et al.  Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021 Sep;28(9):740–746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8437801</ArticleId>
            <ArticleId IdType="pubmed">34381216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon C.J., Tchesnokov E.P., Schinazi R.F., Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021 Jul;297(1):100770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8110631</ArticleId>
            <ArticleId IdType="pubmed">33989635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S., Hill C.S., Sarkar S., et al.  β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021 Aug 2;224(3):415–419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8136050</ArticleId>
            <ArticleId IdType="pubmed">33961695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon J.J., et al.  Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. 2018;62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6105843</ArticleId>
            <ArticleId IdType="pubmed">29891600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A., Gralinski L.E., Johnson C.E., et al.  SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021 Mar;591(7850):451–457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox R.M., Wolf J.D., Plemper R.K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021 Jan;6(1):11–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenke K., Hansen F., Schwarz B., et al.  Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun. 2021;12:2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8052374</ArticleId>
            <ArticleId IdType="pubmed">33863887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter W.P., Holman W., Bush J.A., et al.  Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021 Mar 1;65(5) e02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoo S.H., Fitzgerald R., Fletcher T., et al.  Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021 Aug 27 doi: 10.1093/jac/dkab318. [Online ahead of print] dkab318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkab318</ArticleId>
            <ArticleId IdType="pmc">PMC8598307</ArticleId>
            <ArticleId IdType="pubmed">34450619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer W., Eron J.J., Holman W., et al.  Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021 Jun 17 doi: 10.1101/2021.06.17.21258639. Preprint. 2021.06.17.21258639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.06.17.21258639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The safety of molnupiravir (EIDD-2801) and its effect on viral shedding of SARS-CoV-2 (END-COVID) - full text view - ClinicalTrials.gov (Last accessed on October 20, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Efficacy and safety of molnupiravir (MK-4482) in non-hospitalized adult participants with COVID-19 (MK-4482-002) - full text view - ClinicalTrials.gov. (Last accessed on October 20, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Mahase E. Covid-19: molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021 Oct 4;375:n2422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34607801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merck and Ridgeback's investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate covid-19 in positive interim analysis of phase 3 study. Oct 2021. https://www.merck.com/news/merckand-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-riskof-hospitalization-or-death-by-approximately-50-percent-compared-toplacebo-for-patients-with-mild-or-moderat</Citation>
        </Reference>
        <Reference>
          <Citation>Efficacy and safety of molnupiravir (MK-4482) in hospitalized adult participants with COVID-19 (MK-4482-001) - full text view - ClinicalTrials.gov. (Last accessed on October 20, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Merck and Ridgeback biotherapeutics provide update on progress of clinical development program for molnupiravir, an investigational oral therapeutic for the treatment of mild-to-moderate COVID-19 - Merck.com. (Last accessed on October 20, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Study of MK-4482 for prevention of coronavirus disease 2019 (COVID-19) in adults (MK-4482-013) - full text view - ClinicalTrials.gov (Last accessed on October 20, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Press_Release_Molnupiravir_Interim_Clinical_Results_Final_090721.pdf (heteroworld.com). (Last accessed on October 20, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Optimus announces interim clinical results from phase III clinical trials of molnupiravir conducted in India – ThePrint. (Last accessed on October 20, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Search result, clinical trials registry - India (CTRI). CTRI (Last accessed on October 20, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19 | Reuters. (Last accessed on October 20, 2021).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
